Mutations in the oncogene p53 are present in nearly all types of carcinomas and are commonly inactivated in certain tumor types, resulting in a poor prognosis for these patients. In contrast to the prevailing perspective that targeting p53 protein is not feasible, an increasing number of scholars have found that strategies such as directly or indirectly targeting P53 to enhance or restore the function of wild-type P53, or degrading mutant P53 so that the gain of function caused by it disappears, as well as modulating the immune response and cellular metabolism, can control the progression of tumor cells in different states of P53. This article aims to provide a comprehensive overview of the most recent targeted drugs for solid tumors with different P53 status. At the same time, it conducts a thorough analysis of the efficacy of relevant drugs in patients and puts forward possible reasons for the poor efficacy of some medicines.